Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

The company and the Harvard TH Chan School of Public Health will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon.

The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.

Single-cell RNA sequencing uncovered interactions between colorectal cancer alterations and corresponding immune cell and stromal features.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

The study found that metastatic seeding may occur early in primary tumor development, and treatment of metastases may fuel many of their mutations.

The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.

Investigators reported on detection rates for cancers and precancers in a group of 350 individuals presenting for standard of care colonoscopy.

The company saw orders for its Cologuard colorectal cancer test fall 63 percent during the first 20 days of April because of a decline in standard healthcare visits.

The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.

The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.

Pages

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.